Skip to main content
Solid Biosciences Inc. logo

Solid Biosciences Inc. — Investor Relations & Filings

Ticker · SLDB ISIN · US83422E2046 US Professional, scientific and technical activities
Open in API
Filings indexed 663 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country US United States of America
Listing US SLDB

About Solid Biosciences Inc.

https://www.solidbio.com/

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates. The company develops treatments for rare and devastating neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia (CPVT), and various forms of dilated cardiomyopathy. In addition to its therapeutic pipeline, Solid Biosciences develops enabling technologies, such as innovative libraries of genetic regulators, to improve gene therapy delivery. The company's mission is to improve the lives of patients by uniting experts in science, technology, and disease management.

Recent filings

Filing Released Lang Actions
424B7
Regulatory Filings Classification · 85% confidence The document is a prospectus supplement filed under SEC Rule 424(b)(7) updating the list of selling stockholders and supplementing a previously filed Form S-3 prospectus. It does not itself contain financial statements (so it is not an Annual, Interim, or Earnings report), nor is it an officer certification or a proxy/solicitation or governance policy document. This type of SEC disclosure falls under the general regulatory filings category.
2026-06-05 English
10-Q - Solid Biosciences Inc. (0001707502) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
DEF 14A - Solid Biosciences Inc. (0001707502) (Filer)
Proxy Solicitation & Information Statement
2026-04-23 English
8-K - Solid Biosciences Inc. (0001707502) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 10, 2026, by Solid Biosciences Inc. The content focuses on changes in the Board of Directors, specifically the resignation and reappointment of a director to a different class on the Board. There is no financial data or report attached, and the document is a current report on a management/board change event. This fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a direct report of a board change, not an announcement of a report or certification. Therefore, the correct classification is MANG with high confidence.
2026-04-10 English
S-3 - Solid Biosciences Inc. (0001707502) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used to register securities for resale by existing shareholders. It includes a prospectus for resale of shares by a selling stockholder, describing the offering, use of proceeds, risk factors, and other related information. It is not a financial report, earnings release, or management discussion, but a capital markets filing related to securities registration and resale. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not a brief announcement or certification.
2026-03-19 English
10-K - Solid Biosciences Inc. (0001707502) (Filer)
Annual Report FY 2025
2026-03-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.